TLX2 and ovarian carcinoma: The NCX inhibitor KB-R7943 has been shown to enhance cisplatin-induced cell death in therapy-resistant ovarian carcinoma cells, without affecting sensitive counterparts, and to significantly increase radiation-induced apoptosis in medulloblastoma cells [88,89].